We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts... Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company has a world-class scientific advisory team including recognized global experts in pulmonary hypertension. The Company owns North American rights to develop and commercialize levosimendan and has recently released topline data regarding their Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF). For more information, visit www.tenaxthera.com. Show more
Currently Enrolling Patients in Phase 3 LEVEL Study with 24 Investigative Sites Initiated Secured Global Development and Commercial Rights to Levosimendan forย Treatment of PH-HFpEF Expanded...
Broadens IP protection for oral (TNX-103), IV, and subcutaneous use of levosimendan, and its active metabolites (OR1896 and OR1855), in PH-HFpEFProvides U.S. intellectual property (IP) protection...
Panel of renowned cardiologists, all globally recognized experts in heart failure, will discuss the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection...
First Patient Enrolled in Phase 3 LEVEL Trial Evaluating TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction...
CHAPEL HILL, N.C., March 12, 2024 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.16 | -4.49438202247 | 3.56 | 3.6293 | 3.45 | 11059 | 3.51366862 | CS |
4 | -0.43 | -11.227154047 | 3.83 | 3.9 | 3.44 | 18881 | 3.57199373 | CS |
12 | -0.62 | -15.4228855721 | 4.02 | 4.25 | 3.44 | 37797 | 3.82408952 | CS |
26 | -25.4 | -88.1944444444 | 28.8 | 31.184 | 3.44 | 318766 | 15.05095484 | CS |
52 | -25.44 | -88.2108183079 | 28.84 | 61.152 | 3.44 | 2129453 | 41.54221766 | CS |
156 | -3164.6 | -99.8926767677 | 3168 | 3680 | 3.44 | 1577518 | 149.92671387 | CS |
260 | -2076.6 | -99.8365384615 | 2080 | 5888 | 3.44 | 1359647 | 1052.6466349 | CS |
Symbol | Price | Vol. |
---|---|---|
NVOSNovo Integrated Sciences Inc | $ 1.05 (132.82%) | 310.28M |
GWAVGreenwave Technology Solutions Inc | $ 0.0387 (-7.86%) | 305.13M |
FFIEFaraday Future Intelligent Electric Inc | $ 0.584899 (3.47%) | 223.84M |
SQQQProShares UltraPro Short QQQ | $ 10.02 (0.00%) | 161.89M |
CRKNCrown Electrokinetics Corporation | $ 0.0998 (-12.07%) | 155.13M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions